Obesity Drug Tackles Sleep Apnea, Knee Pain

Eli Lilly's groundbreaking experimental drug, retatrutide, has demonstrated significant promise in recent Phase 3 trial results. Presented at the American Diabetes Association conference in New Orleans, the findings reveal the drug's potential to address multiple health concerns simultaneously.

Retatrutide, a unique "triple G" agent targeting GLP-1, GIP, and glucagon receptors, showed a 60.6% reduction in moderate-to-severe obstructive sleep apnea severity among obese adults. This offers new hope for a condition currently addressed by Lilly's approved drug, Zepbound.

Furthermore, the trial indicated substantial relief for individuals suffering from knee osteoarthritis pain, with reductions of up to 73.1% reported. These comprehensive results complement prior data showing an average 28% body weight loss in patients with obesity and significant blood sugar improvements in those with type 2 diabetes.

Detailed results published in The Lancet on Saturday noted that 2% of diabetes patients on the lowest dose experienced major adverse cardiovascular events. However, the report clarified these events were not necessarily caused by the drug. This development underscores the competitive landscape in the booming obesity and diabetes medication market.